Matthew D. Ringel

Matthew D. Ringel, MD is Professor of Medicine and Director of the Thyroid Cancer Research Laboratory at The Ohio State University (OSU) Comprehensive Cancer Center. He is one of the most influential translational thyroid cancer biologists in the United States, with career-defining contributions to the molecular mechanisms of thyroid cancer invasion, metastasis, and resistance to kinase inhibitor therapy. His laboratory has been continuously funded by the NIH and NCI for over two decades and has trained numerous leaders in thyroid cancer research. Dr. Ringel's research program focuses on the role of BRAF, RAS, and downstream signaling pathways (including PI3K/AKT/mTOR and focal adhesion kinase) in thyroid cancer progression and drug resistance. He identified key mechanisms by which BRAF V600E drives dedifferentiation, invasion, and lymph node metastasis in papillary thyroid cancer, and his work on tumor microenvironment interactions has illuminated how stromal and immune factors modulate thyroid cancer behavior and drug sensitivity. His laboratory has developed murine and cell-based models that have been widely adopted in the field. Beyond basic research, Professor Ringel has translated laboratory discoveries into early-phase clinical trials at OSU. He serves on the American Thyroid Association Thyroid Cancer Guidelines Committee, the NCI Thyroid Cancer Steering Committee, and as editor-in-chief of the journal Thyroid. He has authored over 200 peer-reviewed publications and is a frequent keynote speaker at international thyroid cancer symposia.